Content about Robeco

December 8, 2010

Johnson & Johnson made its courtship with Dutch biotech company Crucell official by acquiring all of the company for $2.3 billion, the two companies said Wednesday.

NEW BRUNSWICK, N.J. — Johnson & Johnson made its courtship with Dutch biotech company Crucell official by acquiring all of the company for $2.3 billion, the two companies said Wednesday.

In a deal that won the full support of Crucell’s management, J&J will pay $32.74 per share for the remainder of Crucell that it doesn’t already own; J&J indirectly controls around 18% of Crucell’s stock through a Dutch affiliate, while Delta Lloyd Asset Management, Robeco and the Van Herk Group control around 15.5%, according to published reports.

October 5, 2010

A few weeks after Johnson & Johnson announced it would purchase the remainder of Dutch...

NEW YORK A few weeks after Johnson & Johnson announced it would purchase the remainder of Dutch biotech firm Crucell it doesn't already own for about $2.4 billion, J&J received backing for the bid.

Crucell recommended the offer to the shareholders but not without receiving some criticism from shareholders Delta Lloyd Asset Management, Robeco and the Van Herk Group, which said the offer from J&J "undervalued" Crucell's worth. The fund managers jointly control at least 15.5% of Crucell, according to Reuters.